Tumor Necrosis Factor Alpha (TNF-a) Agonist -Pipeline Intelligence, 2019
US$ 1,000.00
... the clients within 1-2 Business Days. CmaxInsight’s, “Tumor Necrosis Factor Alpha (TNF-a) Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights ... identifying potential partners with progressing projects for Tumor Necrosis Factor Alpha (TNF-a) Agonist to enhance and expand business potential ...
December 2018
60 pages
Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitor -Pipeline Intelligence, 2019
US$ 1,000.00
... to the clients within 1-2 Business Days. CmaxInsight’s, “Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitor-Pipeline Intelligence, 2019”, report provides ... identifying potential partners with progressing projects for Type 1 Lysophosphatidic Acid Receptor (LPA1) Inhibitor to enhance and expand ...
December 2018
60 pages
Ubiquitin Specific Proteases (USP) Inhibitor -Pipeline Intelligence, 2019
US$ 1,000.00
... clients within 1-2 Business Days. CmaxInsight’s, “Ubiquitin Specific Proteases (USP) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... companies Assess challenges and opportunities that influence Ubiquitin Specific Proteases (USP) Inhibitor R&D Please note: Certain sections in the ...
December 2018
60 pages
Vascular Adhesion Protein 1 (VAP-1) Inhibitor -Pipeline Intelligence, 2019
US$ 1,000.00
... the clients within 1-2 Business Days. CmaxInsight’s, “Vascular Adhesion Protein 1 (VAP-1) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... identifying potential partners with progressing projects for Vascular Adhesion Protein 1 (VAP-1) Inhibitor to enhance and expand business ...
December 2018
60 pages
Vascular Endothelial Growth Factor Inhibitor -Pipeline Intelligence, 2019
US$ 1,000.00
... clients within 1-2 Business Days. CmaxInsight’s, “Vascular Endothelial Growth Factor Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... companies Assess challenges and opportunities that influence Vascular Endothelial Growth Factor Inhibitor R&D Please note: Certain sections in the ...
December 2018
60 pages
Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor -Pipeline Intelligence, 2019
US$ 1,000.00
... to the clients within 1-2 Business Days. CmaxInsight’s, “Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor-Pipeline Intelligence, 2019”, report provides ... by identifying potential partners with progressing projects for Vascular Endothelial Growth Factor A (VEGF-A) Inhibitor to enhance and expand ...
December 2018
60 pages
Vasopressin Receptor Antagonist -Pipeline Intelligence, 2019
US$ 1,000.00
... Business Days. CmaxInsight’s, “Vasopressin Receptor Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... client to understand the landscape of the Vasopressin Receptor Antagonist. Pipeline Covered: This section mentions all the promising ...
December 2018
60 pages
Vasopressin V1 Receptor (V1R) Antagonist -Pipeline Intelligence, 2019
US$ 1,000.00
... clients within 1-2 Business Days. CmaxInsight’s, “Vasopressin V1 Receptor (V1R) Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights ... leading companies Assess challenges and opportunities that influence Vasopressin V1 Receptor (V1R) Antagonist R&D Please note: Certain sections in the ...
December 2018
60 pages
Vasopressin V2 Receptor (V2R) Agonist -Pipeline Intelligence, 2019
US$ 1,000.00
... clients within 1-2 Business Days. CmaxInsight’s, “Vasopressin V2 Receptor (V2R) Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights ... leading companies Assess challenges and opportunities that influence Vasopressin V2 Receptor (V2R) Agonist R&D Please note: Certain sections in the ...
December 2018
60 pages
Vasopressin V2 Receptor (V2R) Antagonist -Pipeline Intelligence, 2019
US$ 1,000.00
... clients within 1-2 Business Days. CmaxInsight’s, “Vasopressin V2 Receptor (V2R) Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights ... leading companies Assess challenges and opportunities that influence Vasopressin V2 Receptor (V2R) Antagonist R&D Please note: Certain sections in the ...
December 2018
60 pages
Viral RNA Polymerase Inhibitor -Pipeline Intelligence, 2019
US$ 1,000.00
... Business Days. CmaxInsight’s, “Viral RNA Polymerase Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... the client to understand the landscape of the Viral RNA Polymerase Inhibitor. Pipeline Covered: This section mentions all the promising ...
December 2018
60 pages
Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist -Pipeline Intelligence, 2019
US$ 1,000.00
... the clients within 1-2 Business Days. CmaxInsight’s, “Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist-Pipeline Intelligence, 2019”, report provides comprehensive ... potential partners with progressing projects for Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist to enhance and expand business ...
December 2018
60 pages
Voltage-Dependent T-Type Calcium Channel Blockers -Pipeline Intelligence, 2019
US$ 1,000.00
... within 1-2 Business Days. CmaxInsight’s, “Voltage-Dependent T-Type Calcium Channel Blockers-Pipeline Intelligence, 2019”, report provides comprehensive ... companies Assess challenges and opportunities that influence Voltage-Dependent T-Type Calcium Channel Blockers R&D Please note: Certain sections in ...
December 2018
60 pages
Wnt Signaling Pathway Inhibitor -Pipeline Intelligence, 2019
US$ 1,000.00
... Days. CmaxInsight’s, “Wnt Signaling Pathway Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... the client to understand the landscape of the Wnt Signaling Pathway Inhibitor. Pipeline Covered: This section mentions all the promising ...
December 2018
60 pages
Xanthine Oxidase Inhibitor -Pipeline Intelligence, 2019
US$ 1,000.00
... 1-2 Business Days. CmaxInsight’s, “Xanthine Oxidase Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Xanthine Oxidase Inhibitor. Pipeline Covered: This section mentions all the promising ...
December 2018
60 pages
Factor VIII Inhibitor -Pipeline Intelligence, 2019
US$ 1,000.00
... 1-2 Business Days. CmaxInsight’s, “Factor VIII Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Factor VIII Inhibitor. Pipeline Covered: This section mentions all the promising therapies ...
December 2018
60 pages
Asthma - Market Outlook, Market Forecast And Competitve Landscape Report - 2018 To 2030
US$ 5,000.00
Thelansis Knowledge Partners 'Asthma' - Market Outlook, Market Forecast and Competitive ... launch date estimation Market Outlook & Market Forecast Historic, current and forecasted market trend (High, ... Mortality 11 years of epidemiology and market projections Incidence/ Prevalence patient population Mortality, ...
December 2018
154 pages
Diabetes - Market Outlook, Market Forecast And Competitve Landscape Report - 2018 To 2030
US$ 5,000.00
Thelansis Knowledge Partners 'Diabetes' - Market Outlook, Market Forecast and Competitive ... launch date estimation Market Outlook & Market Forecast Historic, current and forecasted market trend (High, ... Mortality 11 years of epidemiology and market projections Incidence/ Prevalence patient population Mortality, ...
December 2018
183 pages
Hiv - Market Outlook, Market Forecast And Competitve Landscape Report - 2018 To 2030
US$ 5,000.00
Thelansis Knowledge Partners 'HIV' - Market Outlook, Market Forecast and Competitive ... launch date estimation Market Outlook & Market Forecast Historic, current and forecasted market trend (High, ... Mortality 11 years of epidemiology and market projections Incidence/ Prevalence patient population Mortality, ...
December 2018
196 pages
Advance Stage Melanoma (Stage Iii & Iv) - Market Outlook, Market Forecast And Competitve Landscape Report - 2018 To 2030
US$ 5,000.00
... 'Advance stage Melanoma' - Market Outlook, Market Forecast and Competitive Landscapet report – 2018 to 2030' report comprises of the Disease overview, classifications, stages ... therapies, Off-label therapies, Pipeline assessment, Phase – I, II, III) Patient share Country specific revenue share and trend Market ...
December 2018
154 pages
Melanoma (Stage - I, II III & Iv) - Market Outlook, Market Forecast And Competitve Landscape Report - 2018 To 2030
US$ 5,000.00
Thelansis Knowledge Partners 'Melanoma (Stage - I, II III & IV)' - Market Outlook, Market Forecast and Competitive Landscapet report – ... 2018 to 2030' report comprises of the Disease overview, classifications, stages or severity level, pathogenesis, identified and emerging biomarkers, pipeline assessment ...
December 2018
257 pages
Congenital Cytomegalovirus - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Congenital Cytomegalovirus' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast ... biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement ...
December 2018
217 pages
Lipodystrophy Syndrome - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Congenital Generalized Lipodystrophy' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and ... biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement ...
December 2018
206 pages
Congenital Generalized Lipodystrophy - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Lipodystrophy syndrome' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast Report – ... profile and probable launch date estimation Market Outlook & Market Forecast Historic, current and forecasted market trend (High, Base case, Low) of the ...
December 2018
185 pages
Congenital Herpes Simplex - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Congenital Herpes Simplex' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast Report – ... profile and probable launch date estimation Market Outlook & Market Forecast Historic, current and forecasted market trend (High, Base case, Low) of the ...
December 2018
172 pages
Cytomegalovirus Retinitis - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Cytomegalovirus Retinitis' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast ... biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement ...
December 2018
185 pages
Dravet Syndrome - Market Access, Reimbursement Outlook, Competitive Landscape, Epidemiology and Forecast Report - 2015 To 2030
US$ 6,550.00
Thelansis Knowledge Partners 'Dravet Syndrome' - Market Access, Reimbursement Outlook, Competitive Landscapet, Epidemiology and Forecast ... emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Market access - Country Specific Regulatory scenario s, Patent landscape, reimbursement ...
December 2018
174 pages